Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
about
The evolutionary nature of the cancer immunotherapy revolution.Epithelial-to-Mesenchymal Transition in the Pathogenesis and Therapy of Head and Neck CancerHead and neck cancer: improving outcomes with a multidisciplinary approach.Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.Product review on the Anti-PD-L1 Antibody Atezolizumab.Genomics and advances towards precision medicine for head and neck squamous cell carcinoma.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis.Trial watch: Immune checkpoint blockers for cancer therapy.SEOM clinical guidelines for the treatment of head and neck cancer (2017).Implications of the tumor immune microenvironment for staging and therapeutics.Nivolumab in recurrent/metastatic head and neck cancers.Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.Pembrolizumab for the treatment of bladder cancer.Immunotherapy in head and neck cancer: evidence and perspectives.A correlative analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 expression in oropharyngeal squamous cell carcinoma.PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas.New developments in the management of head and neck cancer – impact of pembrolizumab.Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma.Novel Therapeutic Targets in Cutaneous Squamous Cell Carcinoma.Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.Frameshift events predict anti-PD-1/L1 response in head and neck cancer.Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).Predicting 90-Day Mortality in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma after Curative SurgeryBiomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
P2860
Q38638860-5FE90EAB-778E-4ACA-96A6-7F5825A3012DQ39411041-FDC19117-1012-4C12-A3AB-3AF3720A68DCQ41522410-612D541A-5699-4C95-A4EA-F4A8E4D9A6A5Q41633683-53E2100E-555F-4647-AAAC-36D08B6DDE00Q45074483-0DCED1F7-3224-4898-8323-49749B5CE821Q47098975-226109DD-69BF-4DA6-B542-156CA6E0BEB1Q47120629-DAD5EAA4-7471-4DA2-A819-24B87D2C46C5Q47165377-E7B060DF-462B-4549-8126-738C4ABCAEC6Q47320798-F1F4EBBA-63BB-4512-A2FE-4D13E67F61A6Q47393365-0B1A1AE0-08E9-4A84-8AC1-2E179EEE9703Q47437627-C2A201FA-0B41-442D-A8EE-59273BB9CEBCQ47592007-E9DD4897-960F-4FC6-AE5F-005A0638B14BQ47610092-D815246F-E7E8-4568-9876-760F30132E2AQ48289963-228121D8-7458-4F6A-ACCC-61D83C206553Q49036770-A4335067-CFC1-4A3C-8937-87AB85A08CAFQ49557927-CFA3EC3A-D01F-4558-8B7E-61251AA7A602Q50027076-21CB3768-BB47-40DE-9AC3-CE213A5F0C07Q50054711-2EA3401F-533E-440F-B280-C648765036EEQ50336126-66CE9D76-075B-4E1E-A935-2E9E19505FE1Q50545401-14E37CF7-31A8-47CA-A1D8-C447D2B89655Q52599427-85192A96-922A-426B-B26E-DDD8120F04D8Q52602002-333E6487-510C-413C-BE71-A2C885F72263Q52651819-98A74271-4182-4538-AF28-A09EE1779998Q54269200-C756A8EC-C230-45C6-81FE-B0BC4422B7EDQ55253213-11B8C784-4A06-4CDA-884A-B42DBD10A53FQ55262520-DF01C1A4-7041-4B36-909B-35597698A6AEQ55386599-3836F740-E55D-4645-8A50-1AF64B77A9CEQ55497366-C5B22329-3F51-47C9-BD51-47DE9B8F00E6Q58579220-2658501C-D224-48E0-8F32-E24B648455D6Q58713932-128288CA-AC70-4FC9-81F7-08643B97464D
P2860
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Pembrolizumab for Platinum- an ...... a Single-Arm, Phase II Study.
@en
Pembrolizumab for Platinum- an ...... a Single-Arm, Phase II Study.
@nl
type
label
Pembrolizumab for Platinum- an ...... a Single-Arm, Phase II Study.
@en
Pembrolizumab for Platinum- an ...... a Single-Arm, Phase II Study.
@nl
prefLabel
Pembrolizumab for Platinum- an ...... a Single-Arm, Phase II Study.
@en
Pembrolizumab for Platinum- an ...... a Single-Arm, Phase II Study.
@nl
P2093
P2860
P50
P356
P1476
Pembrolizumab for Platinum- an ...... m a Single-Arm, Phase II Study
@en
P2093
Ammar Sukari
Amy Meister
David G Pfister
Francis Worden
Jared Weiss
Jill Gilbert
Jonathan D Cheng
Joshua Bauml
Lori Wirth
Michael K Gibson
P2860
P304
P356
10.1200/JCO.2016.70.1524
P407
P577
2017-03-22T00:00:00Z